Recent Quotes
My Watchlist
Indicators
MJS Wisconsin Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

62.97 USD -0.04 (-0.06%)
Streaming Delayed Price Updated: 7:07 AM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th... 
From Business Wire News Releases
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: 
From Business Wire News Releases
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new partnership with the Wake Forest University School of Divinity, one of the leading academic and faith-based institutions in the United States,... 
From Business Wire News Releases
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from a new analysis of the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell... 
From Business Wire News Releases
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
From GlobeNewswire News Releases
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor... 
From Business Wire News Releases
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
Kite, a Gilead Company (Nasdaq: GILD), today announced that Frank Neumann, MD, PhD, has joined the company as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will lead Kite’s... 
From Business Wire News Releases
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 4.4% in the company’s quarterly cash dividend, beginning in the first quarter of... 
From Business Wire News Releases
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020. 
From Business Wire News Releases
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation’s largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization, today announced that... 
From Business Wire News Releases
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today... 
From Business Wire News Releases
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern... 
From Business Wire News Releases
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr.... 
From Business Wire News Releases
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination... 
From Business Wire News Releases
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
From GlobeNewswire News Releases
Thinking about trading options or stock in Eli Lilly, Gilead Sciences, GameStop, Boeing, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for LLY, GILD, GME, BA, and ROKU. 
From PR Newswire
Gilead Sciences Announces Updated 2020 Guidance
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has revised certain elements of its full year 2020 guidance. 
From Business Wire News Releases
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based... 
From Business Wire News Releases
Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will provide an overview of the company at the 39th Annual J.P. Morgan Healthcare... 
From Business Wire News Releases
Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences
Financialnewsmedia.com News Commentary 
From PR Newswire
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly... 
From Business Wire News Releases
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and... 
From Business Wire News Releases
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib)
From GlobeNewswire News Releases
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San... 
From Business Wire News Releases
Gilead Sciences to Acquire MYR GmbH
- Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction - 
From PR Newswire
Gilead Sciences to Acquire MYR GmbH
Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus... 
From Business Wire News Releases
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of its Racial Equity Community Impact Fund, which will support high-impact organizations working to tackle racial inequities affecting... 
From Business Wire News Releases
Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the company’s Board of Directors. 
From Business Wire News Releases
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.